Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis
Titel:
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis
Auteur:
Langley, Richard G. B. Reich, Kristian Strand, Vibeke Feldman, Steven R. Paul, Carle Gordon, Kenneth Warren, Richard B. Toth, Darryl Nikaï, Enkeleida Zhu, Baojin Goldblum, Orin Edson-Heredia, Emily Carlier, Hilde Burge, Russel Lin, Chen-Yen Hollister, Kristin Augustin, Matthias